Chimera Investment Corporation News
Where's the Bull?: Cramer's 'Mad Money' Recap (Monday 12/21/20)
As Jim Cramer likes to say, 'There's always a bull market somewhere.' So where are your buying opportunities?
Sell in May?: Cramer's 'Mad Money' Recap (Friday 5/1/20)
Jim Cramer hates this saying, but this market may have run too far. Here's your game plan for next week.
Be a Believer: Cramer's 'Mad Money' Recap (Wednesday 1/22/20)
Jim Cramer is paring back on some high-fliers, but he still believes in this bull and the stalwart stocks that support it.
What's Coming Out of Washington: Cramer's 'Mad Money' Recap
Cramer breaks down what's driving these market gains: taxes, trade, deregulation and a strengthening global economy.
Intel, Exelon, American Electric Power:'Mad Money' Lightning Round
Jim Cramer focuses on Intel, Exelon, Dominion Energy, American Electric Power, 21st Century Fox, Chimera Investment.
Tax Reform Could Boost U.S. Businesses: Cramer's 'Mad Money' Recap
True driving force behind this market remains earnings, says Jim Cramer, but don't ignore the impact of tax reform -- if it happens.
Ford Motor, Constellation Brands, Cypress Semiconductor: 'Mad Money' Lightning Round
Jim Cramer is bullish on Constellation Brands, Cypress Semiconductor and Philip Morris International.
Legislative Circus Is Stalling Stocks: Cramer's 'Mad Money' Recap
Brouhaha over GOP-led health-care deal is not really threatening the Republic. But you should have an investment plan in place.
Chimera Investment (CIM) Weak On High Volume
Trade-Ideas LLC identified Chimera Investment (CIM) as a weak on high relative volume candidate
Tomorrow's Ex-Dividends To Watch: ATAX, RHP, CIM
ATAX RHP CIM are going ex-dividend tomorrow, Tuesday, June 28, 2016
Breaking News
Lululemon Wins a Big Battle Against Peloton
The connected bike company keeps getting bad news as it struggles with demand.
Stock Market Today: Dow Ends up 765 as Wall Street Looks to Shake Off Brutal September
Stocks finished higher Monday as investors kick off October on a positive note after September's dismal losses, with Friday's non-farm payrolls report in focus.
Myovant Sciences Rejects $2.5 Billion Takeover. Now What?
The women's health drug specialist rebuffed an offer from its majority shareholder. A roller coaster ride could be ahead.
Flying Southwest Airlines: 3 Things Every Passenger Should Know
The popular airline works a little different than rivals like JetBlue, Delta, and United.